
Truist raises Progyny price target to $36 after strong Q2 results and growing institutional support
Truist Financial raised its price target for Progyny to $36, signaling nearly 40% upside from its current price. This follows Progyny's record quarterly revenue of $350.51 million, earnings per share of $0.55 beating estimates, and strong client rete...


